Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup

View original at finance.yahoo.com
T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup Samsung’s newest Galaxy devices land at T-Mobile — with on Us offers, benefits worth switching for and a five-year price guarantee Get 5G Home Internet delivered same-day and bundle with a new Galaxy S26 for even more savings BELLEVUE, Wash., February 25, 2…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • This is T-Mobile's richest Galaxy offer ever and the first time T-Mobile customers can get the Galaxy S26 Ultra on Us

    80% confidence

  • T-Mobile's 5G Advanced network unlocks the full performance of the Galaxy S26, turning features like multi-carrier aggregation and uplink enhancements into noticeable real-world improvements in speed, responsiveness and reliability

    80% confidence

  • Combined with built-in benefits and a 5-year price guarantee on best plans, T-Mobile offers unmatched performance and value not found anywhere else

    80% confidence

  • SuperMobile is the best business plan on the best network

    80% confidence

  • T-Mobile's 5G network provides quicker uploads and downloads for large files and smooth 4K streaming even in crowded places like airports and events

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com